006280 - GC Biopharma Corp.

006280 Summary

Biopharma

Stock Price & Overview

₩127,600 +600 (+0.47%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩127,600 ≈ US$91 · Market cap ₩1.5tn (≈ $1.1bn)

006280 Financial Statements

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	1.99	1.68	1.63	1.71	1.54	1.50	1.37	1.33	1.29	1.20	1.05
Cost of Revenue	1.44	1.20	1.14	1.13	1.02	1.06	1.00	0.99	0.92	0.85	0.71
Gross Profit	0.55	0.48	0.48	0.58	0.52	0.44	0.37	0.35	0.37	0.35	0.34
Selling, General & Administrative	0.48	0.45	0.45	0.50	0.45	0.39	0.33	0.30	0.28	0.27	0.25
Operating Income	0.07	0.03	0.03	0.08	0.07	0.05	0.04	0.05	0.09	0.08	0.09
Finance Income	0.02	0.03	0.01	0.02	0.02	0.04	0.01	0.03	0.01	0.01	0.02
Finance Costs	0.07	0.05	0.03	0.03	0.02	0.03	0.03	0.01	0.01	0.01	0.01
Pretax Income	-0.04	-0.04	-0.03	0.09	0.17	0.10	-0.01	0.05	0.07	0.08	0.13
Income Tax Expense	-0.01	0.00	-0.01	0.02	0.04	0.02	0.01	0.02	0.02	0.01	0.03
Net Income	-0.03	-0.04	-0.02	0.07	0.14	0.09	-0.01	0.03	0.06	0.07	0.10
Total Comprehensive Income	-0.04	-0.05	-0.00	0.08	0.14	0.09	-0.01	0.03	0.07	0.07	0.08

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	2.97	2.74	2.64	2.53	2.46	2.15	1.96	1.72	1.70	1.55	1.42
Current Assets	1.37	1.20	1.04	0.98	1.10	1.13	0.96	0.89	0.93	0.80	0.74
Cash & Cash Equivalents	0.05	0.02	0.05	0.11	0.19	0.23	0.10	0.10	0.17	0.06	0.06
Inventories	0.89	0.75	0.52	0.44	0.45	0.44	0.41	0.39	0.38	0.32	0.32
Trade Receivables	0.40	0.39	0.44	0.41	0.42	0.42	0.41	0.39	0.37	0.34	0.29
Non-current Assets	1.60	1.54	1.60	1.55	1.37	1.02	1.00	0.83	0.78	0.75	0.67
Property, Plant & Equipment	0.84	0.80	0.83	0.82	0.80	0.67	0.64	0.56	0.55	0.55	0.50
Intangible Assets	0.34	0.31	0.34	0.31	0.28	0.11	0.10	0.10	0.09	0.07	0.06
Total Liabilities	1.58	1.26	1.10	0.96	0.96	0.88	0.78	0.60	0.59	0.49	0.42
Current Liabilities	1.15	0.77	0.87	0.54	0.55	0.59	0.40	0.30	0.26	0.30	0.31
Non-current Liabilities	0.43	0.49	0.23	0.42	0.41	0.29	0.37	0.29	0.33	0.19	0.11
Total Equity	1.39	1.48	1.54	1.57	1.50	1.27	1.18	1.13	1.11	1.06	1.00
Share Capital	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
Retained Earnings	0.80	0.82	0.87	0.90	0.87	0.76	0.68	0.70	0.68	0.64	0.60

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	99.5	-53.5	-5.5	119.2	126.0	36.0	40.3	14.4	57.9	-1.7	45.2
Cash from Investing Activities	-186.8	-67.9	-150.2	-205.3	-132.1	29.7	-177.9	-86.1	14.8	-111.1	7.8
Purchase of Property, Plant & Equipment	72.4	32.0	79.1	58.0	102.3	82.9	127.5	41.4	29.5	80.7	121.2
Cash from Financing Activities	111.6	93.8	100.5	-2.5	-41.3	81.0	140.8	-4.5	48.2	110.6	-27.6
Dividends Paid	18.8	19.5	24.8	24.0	18.5	12.7	12.4	15.3	15.3	20.5	15.0
Net Change in Cash	24.3	-27.5	-55.2	-88.6	-47.4	146.6	3.2	-76.2	120.9	-2.3	25.5

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	421.2	435.5	497.8	609.5	500.3	383.8	440.9	464.9	417.4	356.8
Cost of Revenue	311.6	312.8	357.5	463.6	345.1	271.0	319.3	319.4	288.9	270.4
Gross Profit	109.5	122.8	140.3	145.9	155.2	112.7	121.5	145.5	128.5	86.4
Selling, General & Administrative	107.8	111.0	135.7	116.7	127.8	104.8	131.6	105.9	110.9	101.4
Operating Income	1.7	11.7	4.6	29.2	27.4	8.0	-10.1	39.6	17.6	-15.0
Finance Income	11.4	10.0	8.2	5.6	0.2	7.7	14.9	5.3	0.6	5.1
Finance Costs	15.9	22.5	20.7	10.2	16.7	26.9	17.1	11.7	11.3	9.7
Pretax Income	-1.6	28.6	-110.1	24.9	33.1	16.7	-44.3	42.9	-8.1	-31.6
Income Tax Expense	-2.7	8.5	-7.3	6.7	0.5	-5.6	-5.6	7.1	0.9	-0.9
Net Income	1.1	20.1	-102.8	18.1	32.7	22.3	-38.7	35.8	-9.1	-30.7
Total Comprehensive Income	3.7	27.7	-95.2	21.9	23.3	7.2	-51.2	33.1	-6.3	-26.1

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	2.82	2.78	2.97	3.19	3.10	3.01	2.74	2.80	2.73	2.68
Current Assets	1.36	1.30	1.37	1.49	1.45	1.42	1.20	1.22	1.17	1.11
Cash & Cash Equivalents	0.04	0.04	0.05	0.06	0.08	0.09	0.02	0.04	0.07	0.05
Inventories	0.89	0.86	0.89	0.85	0.89	0.88	0.75	0.67	0.63	0.59
Trade Receivables	0.35	0.37	0.40	0.54	0.44	0.40	0.39	0.48	0.45	0.44
Non-current Assets	1.46	1.48	1.60	1.70	1.65	1.60	1.54	1.57	1.56	1.58
Property, Plant & Equipment	0.78	0.78	0.84	0.83	0.81	0.83	0.80	0.81	0.82	0.82
Intangible Assets	0.33	0.33	0.34	0.44	0.42	0.42	0.31	0.33	0.33	0.33
Total Liabilities	1.49	1.47	1.58	1.70	1.63	1.54	1.26	1.27	1.24	1.19
Current Liabilities	1.01	1.04	1.15	1.27	1.22	1.04	0.77	0.79	0.75	0.80
Non-current Liabilities	0.48	0.43	0.43	0.43	0.42	0.50	0.49	0.48	0.49	0.39
Total Equity	1.33	1.31	1.39	1.49	1.47	1.47	1.48	1.52	1.49	1.49
Share Capital	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
Retained Earnings	0.80	0.80	0.80	0.88	0.87	0.83	0.82	0.86	0.82	0.83

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	19.8	-24.5	49.4	139.6	-3.4	-86.2	41.7	0.0	-32.8	-62.4
Cash from Investing Activities	-27.2	5.8	-26.2	-50.7	-62.5	-47.3	-20.7	-18.1	-11.8	-17.4
Purchase of Property, Plant & Equipment	14.2	33.0	22.6	26.7	13.1	10.0	6.0	7.0	9.1	9.9
Cash from Financing Activities	7.6	4.2	-39.2	-109.3	59.0	201.1	-43.2	-9.1	61.9	84.2
Dividends Paid	19.6	0.0	0.0	0.0	—	—	0.0	0.0	19.5	0.0
Net Change in Cash	0.2	-14.5	-16.0	-20.4	-6.8	67.5	-22.2	-27.1	17.4	4.4

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

006280 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	1,991.3	+18.5%	+5.2%	+5.8%	+6.6%
Operating income	69.1	+115.4%	-5.2%	+6.6%	-2.8%
Net income	-29.7	—	—	—	—
EPS	₩-2,540	—	—	—	—
Operating cash flow	99.5	—	-5.8%	+22.6%	+8.2%
Shareholders' equity	1,394.3	-5.9%	-3.8%	+1.9%	+3.4%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

006280 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	27.8%	28.7%	29.8%	34.0%	33.9%	29.3%
Operating margin	3.5%	1.9%	2.1%	4.7%	4.8%	3.3%
Net margin	-1.5%	-2.5%	-1.2%	4.1%	8.9%	5.9%
Return on equity	-2.1%	-2.8%	-1.3%	4.5%	9.9%	7.3%
Return on assets	-1.0%	-1.6%	-0.8%	2.8%	5.9%	4.3%
Operating cash flow / revenue	5.0%	-3.2%	-0.3%	7.0%	8.2%	2.4%
Capex / revenue	3.6%	1.9%	4.9%	3.4%	6.7%	5.5%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 006280

Symbol	Last Price
140410Mezzion Pharma Co., Ltd.	₩65,000 +0.0%
068760Celltrion Pharm, Inc.	₩40,850 +0.0%
007390Naturecell Co., Ltd.	₩23,950 +0.2%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
039200Oscotec, Inc.	₩36,600 +1.9%
069620Daewoong Pharma	₩116,100 +1.1%
290650L & C BIO Co., Ltd.	₩47,900 -1.4%
127120JS Link	₩33,600 +12.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
195940HK inno.N Corporation	₩42,050 +0.7%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.